Identification of genetic changes associated with drug resistance by reverse in situ hybridization
1997

Genetic Changes Linked to Drug Resistance in Cancer

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): SF Hoare, CA Freeman, JC Coutts, JM Varley, L James, WN Keith

Primary Institution: University of Glasgow

Hypothesis

Can reverse in situ hybridization (REVISH) effectively detect and map genetic changes associated with drug resistance in cancer cell lines?

Conclusion

The study demonstrates that REVISH can identify and map genetic amplifications related to drug resistance in cancer cell lines.

Supporting Evidence

  • REVISH detected a new amplicon in the doxorubicin-resistant lung cancer cell line, GLC4-ADR.
  • Amplification of the topoisomerase II alpha gene was readily detected and mapped.
  • REVISH identified specific amplifications in both MCF-7 and GLC4 cell lines related to drug resistance.

Takeaway

Scientists used a special technique to find changes in the DNA of cancer cells that make them resistant to medicine. This helps understand how to fight cancer better.

Methodology

The study utilized reverse in situ hybridization (REVISH) and comparative genomic hybridization (CGH) to analyze genetic changes in cancer cell lines selected for drug resistance.

Limitations

The study may not account for all genetic changes due to the complexity of cancer genomes.

Participant Demographics

The study involved human tumor cell lines, specifically MCF-7, MCF-7ADR, GLC4, GLC4-ADR, and CALU3.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication